Physician profile
Ipsa Patel
NPI 1295335289
$4,118.70
in general payments reported to CMS, 2019-2025
15 companies · $60.58 in 2025
The $60.58 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $495 · 2022: $1,344 · 2023: $1,605 · 2024: $614 · 2025: $60.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,266.13 | 2021-2024 | Cimzia |
| Abbvie INC. | $990.24 | 2021-2025 | |
| Lilly USA, LLC | $486.89 | 2021-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $350.36 | 2021-2024 | Saphnelo |
| Amgen INC. | $218.03 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $169.37 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $147.92 | 2023 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $130.93 | 2022 | |
| Glaxosmithkline, LLC. | $106.93 | 2022-2025 | Benlysta, Nucala |
| Radius Health, INC. | $75.50 | 2022-2023 | Tymlos |
| Janssen Biotech, INC. | $70.04 | 2022 | |
| Aurinia Pharma U.S., INC. | $41.06 | 2022-2024 | Lupkynis |
| Genzyme Corporation | $28.26 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2023 | Orencia |
| Alexion Pharmaceuticals, INC. | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ipsa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.